Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166237 | 0.99 | ITGB3 (0.46) | ITGB3ITGA2BACACBTHRAPPARG | |
| SCHEMBL27166225 | 0.90 | ITGB3 (0.46) | ITGB3ITGA2BACACBPPARGPPARA | |
| SCHEMBL27166243 | 0.87 | ACACB (0.43) | ITGB3ITGA2BACACBTHRAPPARG | |
| SCHEMBL8765273 | 0.84 | SMN1; SMN2 (0.46) | ITGB3ITGA2BPPARGMMP13 | |
| SCHEMBL3776724 | 0.82 | LDHA (0.54) | ITGB3ITGA2BPPARGPPARAMMP13 | |
| SCHEMBL6942693 | 0.82 | LDHA (0.54) | ITGB3ITGA2BPPARGPPARAMMP13 | |
| SCHEMBL10785304 | 0.82 | MMP13 (0.43) | ITGB3ITGA2BACACBPPARGPPARA | |
| SCHEMBL6474783 | 0.82 | ITGB3 (0.55) | ITGB3ITGA2BPPARGPPARAPPARD | |
| SCHEMBL16634946 | 0.82 | ITGB3 (0.55) | ITGB3ITGA2BPPARGPPARAPPARD | |
| SCHEMBL29397771 | 0.82 | ITGB3 (0.55) | ITGB3ITGA2BPPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AG (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4583925-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052573-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335840-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4335461-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | GBA1, GBA3, GLS2 | ITGB3 1057/4885ITGA2B 2324/4885ACACB 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.